Galderma says the GLP-1 'Ozempic face' trend is lifting demand for its fillers and Sculptra, with record H1 2026 sales and US growth of 32 percent.
Galderma told CNBC on July 23, 2026 that the GLP-1 "Ozempic face" trend is lifting demand for its fillers and Sculptra biostimulator. First-half sales hit a record 3.1 billion dollars, with US growth of 32 percent outpacing 19 percent elsewhere as weight-loss patients seek facial volume restoration.
Galderma, the Swiss aesthetics company behind Restylane fillers, Sculptra and the Dysport neuromodulator, said on July 23, 2026 that the GLP-1 driven "Ozempic face" trend is starting to lift demand for its injectable portfolio. The comments, made to CNBC on the company's first-half earnings day, tie a cosmetic side effect of weight-loss drugs directly to the fillers and biostimulators clinicians use to restore lost facial volume.
The framing matters because "Ozempic face" is a colloquial label, not a medical diagnosis, and the products pitched to treat it carry very different regulatory footprints. Here is what Galderma actually reported, and what a patient should understand before reading a booming sales chart as if it were medical advice.
Galderma posted record first-half 2026 net sales of about 3.1 billion dollars, up 24.6 percent at constant currency, and raised its full-year guidance to 19 to 21 percent growth. Injectable aesthetics contributed roughly 1.4 billion dollars, up 12.1 percent, split between neuromodulators at 826 million dollars and fillers plus biostimulators at 611 million dollars. Growth in the United States, the largest GLP-1 market, ran at about 32 percent versus 19 percent across the rest of the world. Chief Executive Flemming Ornskov told CNBC the company was "the first one to show that if you take two of our products, filler and Sculptra, you can mitigate some of the facial sagging that you see if you have significant weight loss."
Rapid weight loss on GLP-1 medicines such as semaglutide can reduce fat throughout the body, including the face, leaving some patients with a hollowed or sagging appearance widely nicknamed "Ozempic face." Galderma is positioning a filler plus Sculptra pairing as a way to restore that volume. The picture is not uniformly positive, however. On the same earnings call, management noted that rapid GLP-1 penetration has also contributed to softness in parts of the filler market, while neuromodulators remained the preferred entry treatment for many patients. In other words, weight-loss drugs are reshaping injectable demand, not simply inflating it.
Every product in this story carries a specific label. Ozempic (semaglutide) is FDA-approved for type 2 diabetes, and its sibling Wegovy is FDA-approved for chronic weight management; using either purely for cosmetic weight loss is off-label. Sculptra, a poly-L-lactic acid biostimulator, is FDA-approved to correct facial wrinkles and volume loss, but its specific use for GLP-1 related facial sagging is off-label and supported so far by limited, company-presented interim data rather than large independent trials. Restylane hyaluronic acid fillers are FDA-approved and recently gained new US indications for chin and temple augmentation. Dysport is an FDA-approved neuromodulator; note that Botox itself is made by AbbVie, not Galderma, though headlines often use the name generically.
Watch whether the "Ozempic face" effect shows up as sustained filler and biostimulator growth in future quarters, or stays concentrated in neuromodulators. Watch for peer-reviewed, independent evidence on the filler-plus-Sculptra approach beyond the limited interim data Galderma has presented so far. And watch competition, as rival and newly public regenerative players target the same weight-loss aftercare demand. A booming earnings report signals market momentum, not a treatment recommendation, and any injectable decision belongs with a licensed provider who can assess your face.